Intec Pharma to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Rhea-AI Summary

Intec Pharma Ltd. (NASDAQ: NTEC) announced that CEO Jeffrey A. Meckler will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 21-23, 2020. His presentation is scheduled for September 21 at 2:30 PM (ET) and will be formatted as a fireside chat. Investors can access the live webcast via Intec's website. Intec Pharma specializes in developing drugs using its Accordion Pill technology, aimed at improving drug efficacy and safety, with ongoing trials for treatments related to advanced Parkinson's disease and pain management.

JERUSALEM, Sept. 14, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Date: September 21 – 23, 2020

Company Presentation: Monday, September 21, 2020 at 2:30 pm (ET)

Presenter: Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma

Format: Fireside Chat and One-on-One Investor Meetings

Mr. Meckler's fireside chat will be webcast live and will be accessible through the Events section of Intec Pharma's website at www.intecpharma.com, where it will also be archived for a period of time. 

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in late-stage Phase 3 development for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain indications. In addition, the Company has a research collaboration with Merck & Co.

For more information, visit www.intecpharma.com. Intec Pharma routinely posts information that may be important to investors in the Investor Relations section of its website.

Intec Pharma Investor Contact:

Will O'Connor
Stern IR
+1 212-362-1200
will@sternir.com

 

View original content:http://www.prnewswire.com/news-releases/intec-pharma-to-present-at-oppenheimer-fall-healthcare-life-sciences--medtech-summit-301130396.html

SOURCE Intec Pharma Ltd.

FAQ

When is Intec Pharma's presentation at the Oppenheimer Summit?

Intec Pharma's presentation will take place on September 21, 2020, at 2:30 PM (ET).

Who will present on behalf of Intec Pharma at the Oppenheimer Summit?

CEO Jeffrey A. Meckler will present on behalf of Intec Pharma.

What is the format of Intec Pharma's presentation at the Oppenheimer Summit?

The presentation will be in the form of a fireside chat, followed by one-on-one investor meetings.

Where can I watch Intec Pharma's presentation live?

The presentation will be webcast live on Intec Pharma's website and archived for later viewing.

What technology does Intec Pharma focus on?

Intec Pharma focuses on developing drugs using its proprietary Accordion Pill platform technology.

What are the main products in Intec Pharma's pipeline?

Intec Pharma's pipeline includes Accordion Pill Carbidopa/Levodopa for Parkinson's disease and AP-cannabinoids for pain management.